Visualization of DAS28, SDAI, and CDAI: The magic carpets of rheumatoid arthritis

Gábor Futó, Attila Somogyi, Z. Szekanecz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There has been continuous debate regarding the applicability of various composite measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to further dissect this issue, we numerically and graphically modeled 28-joint disease activity scale (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) by three-dimensional (3D) plotting.We wished to graphically visualize the relative contribution of various elements in the three activity indices to each other. We calculated DAS28 (3 variables), SDAI, and CDAI by the standard equations.We plotted 3D "carpets" showing all combinations of the corresponding variables yielding to DAS28=5.1, DAS28=3.2, DAS28=2.6, SDAI=26, SDAI=11, and SDAI=3.3. We also plotted the 3D carpet for CDAI. In patients with high or moderate disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was not a major confounding factor when calculating DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in joint counts and global assessments in patients with low disease activity (LDA) or those in remission. No reliable assessment of LDA can be performed in cases where ESR >54 mm/h or CRP >20 mg/dl. Similarly, remission cannot be determined if ESR >19 mm/h or CRP >5 mg/dl. As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of remission or LDA. Our results suggest that acute phase reactants are indeed major confounding factors and should be omitted when assessing RA disease activity at least in special cases.

Original languageEnglish
Pages (from-to)623-629
Number of pages7
JournalClinical Rheumatology
Volume33
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Magic
Rheumatoid Arthritis
Blood Sedimentation
C-Reactive Protein
Acute-Phase Proteins
Joint Diseases

Keywords

  • CDAI
  • DAS28
  • Disease activity
  • Rheumatoid arthritis
  • SDAI

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Visualization of DAS28, SDAI, and CDAI : The magic carpets of rheumatoid arthritis. / Futó, Gábor; Somogyi, Attila; Szekanecz, Z.

In: Clinical Rheumatology, Vol. 33, No. 5, 2014, p. 623-629.

Research output: Contribution to journalArticle

@article{a94c45d5c5d74a44bc015885943bdd82,
title = "Visualization of DAS28, SDAI, and CDAI: The magic carpets of rheumatoid arthritis",
abstract = "There has been continuous debate regarding the applicability of various composite measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to further dissect this issue, we numerically and graphically modeled 28-joint disease activity scale (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) by three-dimensional (3D) plotting.We wished to graphically visualize the relative contribution of various elements in the three activity indices to each other. We calculated DAS28 (3 variables), SDAI, and CDAI by the standard equations.We plotted 3D {"}carpets{"} showing all combinations of the corresponding variables yielding to DAS28=5.1, DAS28=3.2, DAS28=2.6, SDAI=26, SDAI=11, and SDAI=3.3. We also plotted the 3D carpet for CDAI. In patients with high or moderate disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was not a major confounding factor when calculating DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in joint counts and global assessments in patients with low disease activity (LDA) or those in remission. No reliable assessment of LDA can be performed in cases where ESR >54 mm/h or CRP >20 mg/dl. Similarly, remission cannot be determined if ESR >19 mm/h or CRP >5 mg/dl. As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of remission or LDA. Our results suggest that acute phase reactants are indeed major confounding factors and should be omitted when assessing RA disease activity at least in special cases.",
keywords = "CDAI, DAS28, Disease activity, Rheumatoid arthritis, SDAI",
author = "G{\'a}bor Fut{\'o} and Attila Somogyi and Z. Szekanecz",
year = "2014",
doi = "10.1007/s10067-014-2559-5",
language = "English",
volume = "33",
pages = "623--629",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Visualization of DAS28, SDAI, and CDAI

T2 - The magic carpets of rheumatoid arthritis

AU - Futó, Gábor

AU - Somogyi, Attila

AU - Szekanecz, Z.

PY - 2014

Y1 - 2014

N2 - There has been continuous debate regarding the applicability of various composite measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to further dissect this issue, we numerically and graphically modeled 28-joint disease activity scale (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) by three-dimensional (3D) plotting.We wished to graphically visualize the relative contribution of various elements in the three activity indices to each other. We calculated DAS28 (3 variables), SDAI, and CDAI by the standard equations.We plotted 3D "carpets" showing all combinations of the corresponding variables yielding to DAS28=5.1, DAS28=3.2, DAS28=2.6, SDAI=26, SDAI=11, and SDAI=3.3. We also plotted the 3D carpet for CDAI. In patients with high or moderate disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was not a major confounding factor when calculating DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in joint counts and global assessments in patients with low disease activity (LDA) or those in remission. No reliable assessment of LDA can be performed in cases where ESR >54 mm/h or CRP >20 mg/dl. Similarly, remission cannot be determined if ESR >19 mm/h or CRP >5 mg/dl. As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of remission or LDA. Our results suggest that acute phase reactants are indeed major confounding factors and should be omitted when assessing RA disease activity at least in special cases.

AB - There has been continuous debate regarding the applicability of various composite measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to further dissect this issue, we numerically and graphically modeled 28-joint disease activity scale (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) by three-dimensional (3D) plotting.We wished to graphically visualize the relative contribution of various elements in the three activity indices to each other. We calculated DAS28 (3 variables), SDAI, and CDAI by the standard equations.We plotted 3D "carpets" showing all combinations of the corresponding variables yielding to DAS28=5.1, DAS28=3.2, DAS28=2.6, SDAI=26, SDAI=11, and SDAI=3.3. We also plotted the 3D carpet for CDAI. In patients with high or moderate disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was not a major confounding factor when calculating DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in joint counts and global assessments in patients with low disease activity (LDA) or those in remission. No reliable assessment of LDA can be performed in cases where ESR >54 mm/h or CRP >20 mg/dl. Similarly, remission cannot be determined if ESR >19 mm/h or CRP >5 mg/dl. As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of remission or LDA. Our results suggest that acute phase reactants are indeed major confounding factors and should be omitted when assessing RA disease activity at least in special cases.

KW - CDAI

KW - DAS28

KW - Disease activity

KW - Rheumatoid arthritis

KW - SDAI

UR - http://www.scopus.com/inward/record.url?scp=84902377884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902377884&partnerID=8YFLogxK

U2 - 10.1007/s10067-014-2559-5

DO - 10.1007/s10067-014-2559-5

M3 - Article

C2 - 24599677

AN - SCOPUS:84902377884

VL - 33

SP - 623

EP - 629

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 5

ER -